Fierce Biotech May 28, 2024
Gabrielle Masson

Gilead Sciences is drawing up $20 million cash to partner with Cartography Biosciences and navigate drug discovery for triple-negative breast cancer and adenocarcinoma, a common form of non-small cell lung cancer.

The multiyear partnership will use Cartography’s computational and genomics platform in efforts to discover novel tumor-selective target antigens and pairs of antigens. Gilead can then opt in on several targets identified through the deal, taking over responsibility for all further research, development and commercialization of the selected programs.

In turn, Cartography will receive $20 million upfront and earn more near-term preclinical milestones as well. The biotech is also eligible to receive an undisclosed amount of development, regulatory and commercial milestones,...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Partnerships, Pharma, Pharma / Biotech, Trends
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article